Onconetix, Inc. (ONCO): Nasdaq/NYSE listing notice — Onconetix receives Nasdaq deficiency notice for late Q3 filing; resolved by filing on Dec 10

Onconetix, Inc.

Received Nasdaq notice on Dec 6, 2024 for failure to timely file Form 10-Q for Q3 2024.
Filed the Q3 2024 Form 10-Q with SEC on Dec 10, 2024, curing the deficiency.
Rule 5250(c)(1) requires timely periodic reports; company now in compliance.
Press release issued Dec 12, 2024 confirming receipt and subsequent filing.

item 3.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Onconetix, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

December 6, 2024, Onconetix, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC informing the Company that, as a result of not having timely filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the “Form 10-Q”) with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the SEC. On December 10, 2024, the Company filed its Form 10-Q with the SEC. This Cur

View on SEC.gov

19 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Onconetix, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-108439

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.